

Nasrien E Ibrahim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10759207/publications.pdf>

Version: 2024-02-01

57
papers

2,649
citations

361045

20
h-index

197535

49
g-index

59
all docs

59
docs citations

59
times ranked

3750
citing authors

#	ARTICLE	IF	CITATIONS
1	2021 Update to the 2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2021, 77, 772-810.	1.2	612
2	Heart Failure With Reduced Ejection Fraction. JAMA - Journal of the American Medical Association, 2020, 324, 488.	3.8	391
3	2017 ACC Expert Consensus Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues About Heart Failure With Reduced Ejection Fraction. Journal of the American College of Cardiology, 2018, 71, 201-230.	1.2	235
4	Established and Emerging Roles of Biomarkers in Heart Failure. Circulation Research, 2018, 123, 614-629.	2.0	200
5	Soluble Urokinase Receptor and Acute Kidney Injury. New England Journal of Medicine, 2020, 382, 416-426.	13.9	149
6	A Novel Circulating Noncoding Small RNA for the Detection of Acute Myocarditis. New England Journal of Medicine, 2021, 384, 2014-2027.	13.9	112
7	Effect of Natriuretic Peptide Assays. Journal of the American College of Cardiology, 2019, 73, 1273-1284.	1.2	98
8	Incident Type 2 Myocardial Infarction in a Cohort of Patients Undergoing Coronary or Peripheral Arterial Angiography. Circulation, 2017, 135, 116-127.	1.6	90
9	A Clinical and Biomarker Scoring System to Predict the Presence of Obstructive Coronary Artery Disease. Journal of the American College of Cardiology, 2017, 69, 1147-1156.	1.2	55
10	Natriuretic Peptides as Inclusion Criteria in Clinical Trials. JACC: Heart Failure, 2020, 8, 347-358.	1.9	53
11	Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. JACC: Heart Failure, 2021, 9, 127-136.	1.9	47
12	Heart failure with mid-range ejection fraction: characterization of patients from the PINNACLE Registry. ESC Heart Failure, 2019, 6, 784-792.	1.4	43
13	Established and Emerging Roles of Biomarkers in Heart Failure Clinical Trials. Circulation: Heart Failure, 2016, 9, .	1.6	42
14	Beyond Natriuretic Peptides for Diagnosis and Management of Heart Failure. Clinical Chemistry, 2017, 63, 211-222.	1.5	41
15	Survival After Heart Transplantation in Patients Bridged With Mechanical Circulatory Support. Journal of the American College of Cardiology, 2020, 75, 2892-2905.	1.2	40
16	A clinical, proteomics, and artificial intelligence-driven model to predict acute kidney injury in patients undergoing coronary angiography. Clinical Cardiology, 2019, 42, 292-298.	0.7	33
17	The Future of Biomarker-Guided Therapy for Heart Failure After the Guiding Evidence-Based Therapy Using Biomarker Intensified Treatment in Heart Failure (GUIDE-IT) Study. Current Heart Failure Reports, 2018, 15, 37-43.	1.3	29
18	Reverse Cardiac Remodeling Following Initiation of Sacubitril/Valsartan in Patients With Heart Failure With and Without Diabetes. JACC: Heart Failure, 2021, 9, 137-145.	1.9	27

#	ARTICLE	IF	CITATIONS
19	Association of an HDL Apolipoproteomic Score With Coronary Atherosclerosis and Cardiovascular Death. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2135-2145.	1.2	26
20	Usefulness of Multiple Biomarkers for Predicting Incident Major Adverse Cardiac Events in Patients Who Underwent Diagnostic Coronary Angiography (from the Catheter Sampled Blood Archive in) Tj ETQq0 0 0 rgBT 10 Overlock 10 Tf 50	0.7	10
21	Sexâ€based differences in biomarkers, health status, and reverse cardiac remodelling in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan. <i>European Journal of Heart Failure</i> , 2020, 22, 2018-2025.	2.9	21
22	Heart rate, beta-blocker use, and outcomes of heart failure with reduced ejection fraction. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019, 5, 3-11.	1.4	20
23	Improvement of Health Status Following Initiation of Sacubitril/Valsartan in Heartâ€Failure and Reduced Ejectionâ€Fraction. <i>JACC: Heart Failure</i> , 2021, 9, 42-51.	1.9	20
24	Racial and Ethnic Differences in Biomarkers, Health Status, and Cardiac Remodeling in Patients With Heart Failure With Reduced Ejection Fraction Treated With Sacubitril/Valsartan. <i>Circulation: Heart Failure</i> , 2020, 13, e007829.	1.6	18
25	Habits Heart App for Patient Engagement in Heart Failure Management: Pilot Feasibility Randomized Trial. <i>JMIR MHealth and UHealth</i> , 2021, 9, e19465.	1.8	17
26	Gender differences in industry payments among cardiologists. <i>American Heart Journal</i> , 2020, 223, 123-131.	1.2	16
27	Neprilysin inhibition, endorphin dynamics, and early symptomatic improvement in heart failure: a pilot study. <i>ESC Heart Failure</i> , 2020, 7, 559-566.	1.4	15
28	Sex Differences in the Management of Advanced Heart Failure. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 88.	0.4	14
29	A clinical and proteomics approach to predict the presence of obstructive peripheral arterial disease: From the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study. <i>Clinical Cardiology</i> , 2018, 41, 903-909.	0.7	13
30	Diagnostic and Prognostic Utilities of Insulin-Like Growth Factor Binding Protein-7 in Patients With Dyspnea. <i>JACC: Heart Failure</i> , 2020, 8, 415-422.	1.9	13
31	Singleâ€Molecule Counting of Highâ€Sensitivity Troponin I in Patients Referred for Diagnostic Angiography: Results From the CASABLANCA (Catheter Sampled Blood Archive in Cardiovascular) Tj ETQq1 1 0.7843d 4 rgBT 10 Overlock	1.0	10
32	Derivation and External Validation of a Highâ€Sensitivity Cardiac Troponinâ€Based Proteomic Model to Predict the Presence of Obstructive Coronary Artery Disease. <i>Journal of the American Heart Association</i> , 2020, 9, e017221.	1.6	12
33	Worsening Renal Function during Management for Chronic Heart Failure with Reduced Ejection Fraction: Results From the Pro-BNP Outpatient Tailored Chronic Heart Failure Therapy (PROTECT) Study. <i>Journal of Cardiac Failure</i> , 2017, 23, 121-130.	0.7	10
34	Proteomic Signatures During Treatment in Different Stages of Heart Failure. <i>Circulation: Heart Failure</i> , 2020, 13, e006794.	1.6	10
35	Serial Echocardiographic Characteristics, Novel Biomarkers and Cachexia Development in Patients with Stable Chronic Heart Failure. <i>Journal of Cardiovascular Translational Research</i> , 2016, 9, 429-431.	1.1	9
36	Blood kidney injury moleculeâ€1 predicts short and longer term kidney outcomes in patients undergoing diagnostic coronary and/or peripheral angiographyâ€Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. <i>American Heart Journal</i> , 2019, 209, 36-46.	1.2	9

#	ARTICLE	IF	CITATIONS
37	Endothelin-1 Measurement in Patients Undergoing Diagnostic Coronary Angiography—Results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) Study. <i>Clinical Chemistry</i> , 2018, 64, 1617-1625.	1.5	8
38	Are Guidelines Merely Suggestions?. <i>Journal of the American College of Cardiology</i> , 2018, 72, 367-369.	1.2	7
39	Understanding the Mechanistic Benefit of Heart Failure Drugs Matters. <i>Journal of the American College of Cardiology</i> , 2020, 76, 2752-2754.	1.2	7
40	Predicting new-onset HF in patients undergoing coronary or peripheral angiography: results from the Catheter Sampled Blood Archive in Cardiovascular Diseases (CASABLANCA) study. <i>ESC Heart Failure</i> , 2018, 5, 240-248.	1.4	6
41	Challenges and the innovations in the care of advanced heart failure patients during COVID-19. <i>Heart Failure Reviews</i> , 2022, 27, 235-238.	1.7	6
42	Gender Differences in Medicare Payments Among Cardiologists. <i>JAMA Cardiology</i> , 2021, 6, 1432.	3.0	6
43	Renin-Angiotensin System Blockade in Heart Failure. <i>Journal of the American College of Cardiology</i> , 2017, 69, 820-822.	1.2	4
44	Monitoring Biomarkers in Patients Receiving Nephilysin Inhibitors. <i>Current Emergency and Hospital Medicine Reports</i> , 2018, 6, 8-16.	0.6	4
45	Left ventricular outflow tract pseudoaneurysm formation following three aortic valve replacement surgeries. <i>Heart Views</i> , 2015, 16, 161.	0.1	4
46	Multiple Cardiac Biomarker Testing Among Patients With Acute Dyspnea From the ICON-RELOADED Study. <i>Journal of Cardiac Failure</i> , 2022, 28, 226-233.	0.7	4
47	Serial Heart Rates, Guideline-Directed Beta Blocker Use, and Outcomes in Patients With Chronic Heart Failure With Reduced Ejection Fraction. <i>American Journal of Cardiology</i> , 2017, 120, 803-808.	0.7	3
48	Sodium-Glucose Co-Transporter 2 Inhibitors and Insights from Biomarker Measurement in Heart Failure Patients. <i>Clinical Chemistry</i> , 2021, 67, 79-86.	1.5	3
49	How Feeling Like an Imposter Can Impede Your Success. <i>JACC: Case Reports</i> , 2021, 3, 347-349.	0.3	3
50	Alteration of medical therapy in patients with heart failure relative to change in symptom severity. <i>ESC Heart Failure</i> , 2019, 6, 1085-1087.	1.4	2
51	It is time for consistency in the use of biomarkers in heart failure clinical trials. <i>European Journal of Heart Failure</i> , 2020, 22, 90-91.	2.9	2
52	The Need to Innovate and Accelerate Clinical Trial Performance. <i>Journal of the American College of Cardiology</i> , 2020, 76, 14-16.	1.2	2
53	Using mHealth interventions to promote cardiovascular health. <i>Acta Cardiologica</i> , 2019, 74, 283-285.	0.3	1
54	Rebranding Natriuretic Peptides. <i>Clinical Chemistry</i> , 2021, 67, 4-5.	1.5	1

#	ARTICLE	IF	CITATIONS
55	The case for targeted mid-life interventions to prevent cardiovascular disease. Acta Cardiologica, 2020, 75, 805-807.	0.3	0
56	Biomarkers and Precision Medicine in Heart Failure. , 2020, , 449-466.e3.		0
57	Advances in Heart Failure Management: Improving Outcomes With Innovation. Reviews in Cardiovascular Medicine, 2017, 18, S1-S16.	0.5	0